ACE-031
Also known as ActRIIB-Fc, ACVR2B-Fc
An investigational soluble activin receptor type IIB fusion protein studied for blocking myostatin-family ligands and increasing muscle mass in wasting disorders.
Overview
ACE-031 is not a simple peptide. It is a soluble activin receptor type IIB fusion protein designed to bind ligands such as myostatin and related TGF-beta family members.
The Science
The target is the muscle-growth brake system. Blocking myostatin-family signaling can increase muscle mass in animal models and some human research settings, but pathway breadth creates safety questions.
- Myostatin inhibition - reduces one negative regulator of muscle growth.
- Activin signaling - broader than myostatin alone, which affects risk interpretation.
- Muscle-wasting research - studied in neuromuscular and cachexia-related contexts.
Evidence Snapshot
ACE-031 is a high-impact pathway intervention, not a general fitness peptide. Muscle size, function, vascular findings, and off-target TGF-beta-family effects all matter.
Related
More in Growth Hormone
CJC-1295
Research compoundGrowth Hormone
A synthetic analog of growth-hormone-releasing hormone (GHRH) engineered for extended half-life, studied for prolonged stimulation of pulsatile GH and IGF-1 release — a tool researchers and self-experimenters use to explore their own endocrine biology.
GDF-8
Research compoundGrowth Hormone
Not a peptideProtein cytokine
A TGF-beta family protein better known as myostatin, the major negative regulator of skeletal muscle growth and a target in muscle-wasting research.
GHRP-6
Research compoundGrowth Hormone
A growth hormone secretagogue peptide that activates ghrelin/GHS receptors and is studied for GH release, appetite signaling, and endocrine-axis pharmacology.